Literature DB >> 20858517

HIV-1 Vpu targets cell surface markers CD4 and BST-2 through distinct mechanisms.

Amy Andrew1, Klaus Strebel.   

Abstract

Vpu is a small integral membrane protein encoded by HIV-1 and some SIV isolates. The protein is known to induce degradation of the viral receptor molecule CD4 and to enhance the release of newly formed virions from the cell surface. Vpu accomplishes these two functions through two distinct mechanisms. In the case of CD4, Vpu acts as a molecular adaptor to connect CD4 to an E3 ubiquitin ligase complex resulting in CD4 degradation by cellular proteasomes. This requires signals located in Vpu's cytoplasmic domain. Enhancement of virus release on the other hand involves the neutralization of a cellular host factor, BST-2 (also known as CD317, HM1.24, or tetherin) and requires Vpu's TM domain. The current review discusses recent advances on the role of Vpu in controlling degradation of CD4 and in regulating virus release. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20858517      PMCID: PMC2967615          DOI: 10.1016/j.mam.2010.08.002

Source DB:  PubMed          Journal:  Mol Aspects Med        ISSN: 0098-2997


  118 in total

1.  Broad-spectrum inhibition of retroviral and filoviral particle release by tetherin.

Authors:  Nolwenn Jouvenet; Stuart J D Neil; Maria Zhadina; Trinity Zang; Zerina Kratovac; Youngnam Lee; Matthew McNatt; Theodora Hatziioannou; Paul D Bieniasz
Journal:  J Virol       Date:  2008-11-26       Impact factor: 5.103

2.  Inhibition of Lassa and Marburg virus production by tetherin.

Authors:  Toshie Sakuma; Takeshi Noda; Shuzo Urata; Yoshihiro Kawaoka; Jiro Yasuda
Journal:  J Virol       Date:  2008-12-17       Impact factor: 5.103

3.  Tetherin-mediated restriction of filovirus budding is antagonized by the Ebola glycoprotein.

Authors:  Rachel L Kaletsky; Joseph R Francica; Caroline Agrawal-Gamse; Paul Bates
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-28       Impact factor: 11.205

4.  HIV-1 antagonism of CD317 is species specific and involves Vpu-mediated proteasomal degradation of the restriction factor.

Authors:  Christine Goffinet; Ina Allespach; Stefanie Homann; Hanna-Mari Tervo; Anja Habermann; Daniel Rupp; Lena Oberbremer; Christian Kern; Nadine Tibroni; Sonja Welsch; Jacomine Krijnse-Locker; George Banting; Hans-Georg Kräusslich; Oliver T Fackler; Oliver T Keppler
Journal:  Cell Host Microbe       Date:  2009-03-19       Impact factor: 21.023

5.  HM1.24 is internalized from lipid rafts by clathrin-mediated endocytosis through interaction with alpha-adaptin.

Authors:  Naoko Masuyama; Toshio Kuronita; Rika Tanaka; Tomonori Muto; Yuko Hirota; Azusa Takigawa; Hideaki Fujita; Yoshinori Aso; Jun Amano; Yoshitaka Tanaka
Journal:  J Biol Chem       Date:  2009-04-08       Impact factor: 5.157

6.  Suppression of Tetherin-restricting activity upon human immunodeficiency virus type 1 particle release correlates with localization of Vpu in the trans-Golgi network.

Authors:  Mathieu Dubé; Bibhuti Bhusan Roy; Pierre Guiot-Guillain; Johanne Mercier; Julie Binette; Grace Leung; Eric A Cohen
Journal:  J Virol       Date:  2009-02-25       Impact factor: 5.103

7.  Vpu enhances HIV-1 virus release in the absence of Bst-2 cell surface down-modulation and intracellular depletion.

Authors:  Eri Miyagi; Amy J Andrew; Sandra Kao; Klaus Strebel
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-05       Impact factor: 11.205

8.  Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2.

Authors:  Bin Jia; Ruth Serra-Moreno; William Neidermyer; Andrew Rahmberg; John Mackey; Ismael Ben Fofana; Welkin E Johnson; Susan Westmoreland; David T Evans
Journal:  PLoS Pathog       Date:  2009-05-15       Impact factor: 6.823

9.  Vpu antagonizes BST-2-mediated restriction of HIV-1 release via beta-TrCP and endo-lysosomal trafficking.

Authors:  Richard S Mitchell; Chris Katsura; Mark A Skasko; Katie Fitzpatrick; David Lau; Autumn Ruiz; Edward B Stephens; Florence Margottin-Goguet; Richard Benarous; John C Guatelli
Journal:  PLoS Pathog       Date:  2009-05-29       Impact factor: 6.823

10.  Mutation of a single residue renders human tetherin resistant to HIV-1 Vpu-mediated depletion.

Authors:  Ravindra K Gupta; Stéphane Hué; Torsten Schaller; Ernst Verschoor; Deenan Pillay; Greg J Towers
Journal:  PLoS Pathog       Date:  2009-05-22       Impact factor: 6.823

View more
  24 in total

1.  C-terminal hydrophobic region in human bone marrow stromal cell antigen 2 (BST-2)/tetherin protein functions as second transmembrane motif.

Authors:  Amy J Andrew; Sandra Kao; Klaus Strebel
Journal:  J Biol Chem       Date:  2011-09-21       Impact factor: 5.157

Review 2.  HIV-1 Vpu - an ion channel in search of a job.

Authors:  Klaus Strebel
Journal:  Biochim Biophys Acta       Date:  2013-07-03

3.  Vpu is the main determinant for tetraspanin downregulation in HIV-1-infected cells.

Authors:  Marie Lambelé; Herwig Koppensteiner; Menelaos Symeonides; Nathan H Roy; Jany Chan; Michael Schindler; Markus Thali
Journal:  J Virol       Date:  2015-01-07       Impact factor: 5.103

Review 4.  Delineating HIV-associated neurocognitive disorders using transgenic models: the neuropathogenic actions of Vpr.

Authors:  Christopher Power; Elizabeth Hui; Pornpun Vivithanaporn; Shaona Acharjee; Maria Polyak
Journal:  J Neuroimmune Pharmacol       Date:  2011-09-15       Impact factor: 4.147

5.  Antibody-mediated enhancement of HIV-1 and HIV-2 production from BST-2/tetherin-positive cells.

Authors:  Eri Miyagi; Amy Andrew; Sandra Kao; Takeshi Yoshida; Klaus Strebel
Journal:  J Virol       Date:  2011-09-14       Impact factor: 5.103

6.  Cooperation of the Ebola Virus Proteins VP40 and GP1,2 with BST2 To Activate NF-κB Independently of Virus-Like Particle Trapping.

Authors:  Maryan G Rizk; Christopher F Basler; John Guatelli
Journal:  J Virol       Date:  2017-10-27       Impact factor: 5.103

7.  Differential effects of human immunodeficiency virus type 1 Vpu on the stability of BST-2/tetherin.

Authors:  Amy J Andrew; Eri Miyagi; Klaus Strebel
Journal:  J Virol       Date:  2010-12-29       Impact factor: 5.103

8.  A Coronavirus E Protein Is Present in Two Distinct Pools with Different Effects on Assembly and the Secretory Pathway.

Authors:  Jason W Westerbeck; Carolyn E Machamer
Journal:  J Virol       Date:  2015-07-01       Impact factor: 5.103

Review 9.  The role of ubiquitylation in immune defence and pathogen evasion.

Authors:  Xiaomo Jiang; Zhijian J Chen
Journal:  Nat Rev Immunol       Date:  2011-12-09       Impact factor: 53.106

10.  HIV-1 accessory proteins: Vpu and Vif.

Authors:  Amy Andrew; Klaus Strebel
Journal:  Methods Mol Biol       Date:  2014
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.